Bristol Myers Squibb Company $BMY Shares Bought by Burford Brothers Inc.

Key Points

• Institutional interest increased: Burford Brothers Inc. more than tripled its Bristol Myers Squibb holdings to 23,457 shares, while institutional investors collectively owned 76.41% of BMY.
• Analysts remain broadly positive: Several firms raised price targets, with the stock carrying a “Moderate Buy” consensus rating and an average target of $66.06.
• Strong financial performance and income: Bristol Myers Squibb beat quarterly earnings and revenue estimates, reported 5.7% year-over-year revenue growth, and paid a quarterly dividend of $0.63, representing a 3.7% yield.

Burford Brothers Inc. grew its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 210.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,457 shares of the biopharmaceutical company's stock after buying an additional 15,897 shares during the quarter. Burford Brothers Inc.'s holdings in Bristol Myers Squibb were worth $1,352,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Brighton Jones LLC lifted its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its position in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank increased its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock valued at $1,164,000 after buying an additional 3,277 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $221,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $405,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research reports. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Truist Financial reiterated a "buy" rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Argus raised Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 target price on the stock in a report on Wednesday, August 5th. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Finally, Guggenheim reiterated a "buy" rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Price Performance

BMY stock opened at $68.06 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock's 50 day moving average price is $62.73 and its 200 day moving average price is $59.87. The firm has a market cap of $139.03 billion, a P/E ratio of 14.99, a PEG ratio of 0.32 and a beta of 0.23. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is 55.51%.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.05% of the stock is owned by corporate insiders.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging long-term data for Camzyos from the EXPLORER-LTE study supported renewed investor interest in the heart-failure drug. The data add to expectations that Camzyos can remain an important growth product for Bristol Myers Squibb. Bristol Myers Squibb Gains on Camzyos Data
• Positive Sentiment: Analysts and market commentators highlighted bullish technical indicators, strong recent returns, and Bristol Myers Squibb’s outperformance versus the broader healthcare sector. These factors may be attracting momentum-oriented investors. Revisiting Stock Picks
• Neutral Sentiment: RBC Capital maintained a Hold rating, reflecting a balanced view: BMY’s valuation and improving business momentum are constructive, but the stock’s strong run may already incorporate much of the favorable news. RBC Capital Maintains Hold Rating
• Negative Sentiment: Bristol Myers Squibb voluntarily paused enrollment in its zola-cel autoimmune cell-therapy trials after inflammatory side effects emerged during safety monitoring. The pause raises concerns about the therapy’s risk profile, delays a potentially important pipeline program, and may increase scrutiny of trial-disclosure practices. What Does the BMY Trial Pause Mean for Its Pipeline?
• Negative Sentiment: Broader reporting that Novartis and Bristol Myers Squibb halted autoimmune trials following deaths or serious side effects reinforces concerns about the safety and development risk of experimental cell therapies. Drugmakers Halt Autoimmune Trials

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source